Mural Oncology plc

Mural Oncology — Investor Presentation (January 2024)

29 slides from Mural Oncology's investor presentation, Jan 8, 2024

  1. Slide 1: Investor Presentation January 2024

    INVESTOR PRESENTATION January 2024 Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Certain statements set forth in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. The words “anticipate,” “believe,” “expect,” “may,” “will” and similar expressions are intended

  3. Slide 3: Section 1: Executive Summary

    Section 1: Executive Summary

  4. Slide 4: Mural Oncology - Building a Novel Engineered Cytokine Company

    Mural Oncology is a new, independent publicly traded company with $275M in cash1, providing runway into 4Q 2025. Highly experienced senior leadership team with deep immuno-oncology experience Nemvaleukin is an intrinsically active, stable fusion protein which does not degrade into native-IL-2 and is

  5. Slide 5: Industry Leading Management Team and Board of Directors

    Industry Leading Management Team and Board of Directors Executive Team Caroline Loew, Ph.D. CEO Vicki Goodman, M.D. CMO Maiken Keson-Brookes CLO Adam Cutler CFO Board of Directors Caroline Loew, Ph.D. Susan Altschuller, Ph.D., MBA Francis Cuss, M.B., B.Chir., FRCP Scott Jackson, MBA - Chairman Benja

  6. Slide 6: Pipeline Overview – Near-Term Milestones

    Pipeline Overview – Near-Term Milestones Discovery Preclinical Phase 1 Phase 2 Phase 3 Indication Dosing Nemvaleukin (IV) Monotherapy and Combination with Pembrolizumab (Potentially Registrational) Platinum Resistant Ovarian Cancer (PROC) (ARTISTRY-7) Nemvaleukin (IV) Monotherapy (Potentially Regist

  7. Slide 7: Mural’s Novel Approach to Cytokine Design Seeks to Elevate Immunotherapy Treatment

    Mural’s Novel Approach to Cytokine Design Seeks to Elevate Immunotherapy Treatment for Cancer Patients Extracted from Lei Q, et al. Front. Cell Dev. Biol. 2020;8:00672 GlobalData Thematic Research: Immuno-Oncology Minority of patients respond to anti-PD-(L)1 therapy Responders often experience disea

  8. Slide 8: Mural's Core Competency: Fit-For-Purpose Engineered Cytokines

    Mural's Core Competency: Fit-For-Purpose Engineered Cytokines Abbrev.: Tregs: regulatory T cells; rhIL: recombinant human IL; IL-2R: IL-2 receptor; IL-2Rα: IL-2R alpha, IL-18BP: IL-18 binding protein Intrinsically active stable, not degraded fusion protein, sterically occluded from binding to the hi

  9. Slide 9: Section 2: Nemvaleukin Alfa

    Section 2: Nemvaleukin Alfa

  10. Slide 10: Nemvaleukin is Meaningfully Differentiated from Native IL-2

    Nemvaleukin is Meaningfully Differentiated from Native IL-2 Source: Lopes J, et al. J Immunother Cancer. 2020;8:e000673. Abbrev.: IL-2R: IL-2 receptor; hdIL-2: high dose IL-2 b  a High-Affinity Receptor-Bearing Cell b  Intermediate-Affinity Receptor-Bearing Cell CD8+ T cell NK cell Treg cell CD25

  11. Slide 11: Nemvaleukin Design Detail

    Nemvaleukin Design Detail Abbrev.: IL-2R: IL-2 receptor; IL-2Rα: IL-2R alfa Results in stable fusion protein Sterically occluded from high-affinity IL-2R Minimizes immunogenicity risk Intrinsically active No metabolic or proteolytic conversion Rigorous Selection of α Subunit for Fusion to IL-2 Appli

  12. Slide 12: Clinical Pharmacodynamic Effects of Nemvaleukin: More NK Cells and Fewer Tregs

    Clinical Pharmacodynamic Effects of Nemvaleukin: More NK Cells and Fewer Tregs than High-Dose IL-21,2 Nemvaleukin data are from the 6 μg/kg cohort in Part A of ARTISTRY-1. For fold change plots, data are mean + SE (N=10). For time course plot, data are mean + SD (N=12). 1. Vaishampayan et al. Oral A

  13. Slide 13: Nemvaleukin Characteristics and Significance

    Nemvaleukin Characteristics Significance Designed to include IL-2Rα and minimize non-native sequences Potentially reduced immunogenicity and more native-like-IL-2 signaling potential Does not require activation by tumor intrinsic factors Immediately active upon delivery Limited binding to high affin

  14. Slide 14: Nemvaleukin: Deliberate and Focused Development Program

    Nemvaleukin: Deliberate and Focused Development Program Abbrev.: IV: Intravenous; SC: Subcutaneous Type of Clinical Trial Trial Name / Phase Tumor Types Dosing Mono or Combo? Status Foundational ARTISTRY-1 Phase 1/2 Advanced solid tumors Daily IVx5 Multiple responses in mono and combo Trial complete

  15. Slide 15: ARTISTRY-1: First-In-Human Trial of IV Nemvaleukin

    ARTISTRY-1: First-In-Human Trial of IV Nemvaleukin Global, Multicenter, Open-Label Phase 1/2 Trial Dose Expansion NCTO2799095 1. Patients from Parts A and B could roll over to Part C upon progression or stable disease (after > 4 cycles) on monotherapy 2. Nemvaleukin daily Q5D, then off treatment for

  16. Slide 16: Nemvaleukin’s Adverse Event Profile in ARTISTRY-1

    Nemvaleukin’s Adverse Event Profile in ARTISTRY-1 Was Consistent with Our Expectations Based on its Mechanism of Action Data as of March 27, 2023 Administered on outpatient basis; most frequent AEs were manageable with supportive care AE profile consistent with nemvaleukin mechanism of action Monoth

  17. Slide 17: ARTISTRY-1: Combination with Pembrolizumab Demonstrated Durable Responses

    ARTISTRY-1: Nemvaleukin Combination Treatment with Pembrolizumab Demonstrated Durable Responses Data cut off Mar 27 2023 Abbrev.: BEV: bevacizumab; CBP: carboplatin; CDDP: cisplatin; CR: complete response; DOC: docetaxel; FDA: Food and Drug Administration; GEM: gemcitabine; mo: month; NIR: niraparib

  18. Slide 18: ARTISTRY-7: Phase 3 Potentially Registrational Study in Platinum-Resistant Ovarian Cancer

    ARTISTRY-7: Phase 3 / Potentially Registrational Study for Platinum-Resistant Ovarian Cancer Herzog T et al. Poster presented at the Society for Gynecologic Cancers Annual Meeting (SGO), Phoenix, AZ, March 18-21, 2022 Investigational Nemvaleukin IV ± Pembrolizumab Versus Pembrolizumab Monotherapy or

  19. Slide 19: ARTISTRY-1: Durable Monotherapy Responses in Melanoma (Part B)

    Responses per RECIST v1.1 ARTISTRY-1: Nemvaleukin Demonstrated Durable Monotherapy Responses in Melanoma (Part B) All responders had been on prior CPI therapy and progressed FDA Orphan Drug and Fast Track designations, as well as MHRA’s ILAP Innovation Passport, granted in mucosal melanoma Data supp

  20. Slide 20: ARTISTRY-6: Potentially Registrational Trial in Mucosal Melanoma

    Cohort 2 of ARTISTRY-6: Phase 2 / Potentially Registrational Trial of Nemvaleukin in Mucosal Melanoma https://clinicaltrials.gov, NCT04830124 Key eligibility criteria 1 Unresectable and/or metastatic mucosal melanoma Patient has received anti–PD(L)-1 ± anti–CTLA-4 therapy No more than 1 prior system

  21. Slide 21: Focused on Initial, Potentially Registrational Indications with Expansion Opportunities

    Focused on Initial, Potentially Registrational Indications with Compelling Expansion Opportunities Clarivate Epidemiology; Estimated number of patients in the U.S. and Europe Represents 3rd line PROC patients Abbrev.: CPI: Checkpoint Inhibitor; MOA: Mechanism of Action; RCC: Renal Cell Carcinoma; NS

  22. Slide 22: Exploration of Alternative Dose Administration and Schedule Underway

    Exploration of Alternative Dose Administration and Schedule Underway to Further Optimize Nemvaleukin Profile 5x 2x ARTISTRY-3 Phase 1 Monotherapy 5x daily Q3W Future Nemvaleukin Clinical Trials ARTISTRY-1 Phase 1/2 Monotherapy / Dose Escalation / Expansion / Combination ARTISTRY-6 Phase 2 Mucosal Me

  23. Slide 23: Section 3: Additional Pipeline Programs

    Section 3: Additional Pipeline Programs

  24. Slide 24: IL-18 Engineering: Resist IL-18BP Checkpoint

    IL-18 Engineering: Resist IL-18BP Checkpoint to Unleash the Therapeutic Potential of IL-18 Challenge to IL-18 Internal expertise in protein engineering Mural Solution: Engineer IL-18 variants resistant to IL-18BP Resist IL-18 neutralization by immune checkpoint IL-18BP Retain and optimize IL-18 acti

  25. Slide 25: Preclinical Studies Demonstrated Improved Potency with Resistance to IL-18BP

    Preclinical Studies Demonstrated Improved Potency with Maximal Resistance to IL-18BP Inhibition No Detectable Binding of Variants to IL-18BP Note: No detectable binding of IL18 Variants to hIL-18BP WT-IL18 IL18 Variant 1 IL18 Variant 2 Variants with Broad Range of Potency vs WT IL-18 with Resistance

  26. Slide 26: IL-12 Engineering: Tumor Site-Specific Assembly of Functional IL-12

    IL-12 Engineering: Tumor Site-Specific Assembly of Functional IL-12 Designed to Limit Systemic IL-12 Exposure IL-12 subunits are fused to Mural’s antibody fragments Tumor-targeted IL-12 subunits Non-targeted engineered inactive subunits Tumor-targeting Antibody fragments p35 Treat with targeted p35

  27. Slide 27: Preclinical Studies Provide Proof of Mechanism with Clear Pharmacodynamic Response

    Preclinical Studies Provide Proof of Mechanism with a Clear Pharmacodynamic Response Source: Company internal data on file Abbrev: rhIL-12: recombinant human IL-12; GLP: good laboratory practice PBMC Humanized NCG Mouse Model In general, IL-12 anti-tumor activity observed in preclinical studies has

  28. Slide 28: Mural Oncology - Building a Novel Engineered Cytokine Company

    Mural Oncology is a new, independent publicly traded company with $275M in cash1, providing runway into 4Q 2025. Highly experienced senior leadership team with deep immuno-oncology experience Nemvaleukin is an intrinsically active, stable fusion protein which does not degrade into native-IL-2 and is

  29. Slide 29: Thank You!

    THANK YOU!

Mural Oncology — Investor Presentation (January 2024) on 6ix